SCHEDULE: Armistice Capital Holds 11.43% Stake in Aridis Pharma
Beneficial Ownership Report
Armistice Capital and Steven Boyd report a continued 11.43% beneficial ownership stake in Aridis Pharmaceuticals, Inc. common stock.
Summary
- Armistice Capital, LLC and Steven Boyd collectively report beneficial ownership of 5,096,251 shares of Aridis Pharmaceuticals, Inc. Common Stock.
- This represents 11.43% of the outstanding Common Stock.
- The percentage is based on 44,574,021 shares outstanding as of September 30, 2024, as reported in Aridis Pharmaceuticals' Form 10-Q filed on November 6, 2024.
- Armistice Capital, LLC, as the investment manager, exercises voting and investment power over these securities held by Armistice Capital Master Fund Ltd.
- Steven Boyd, as the managing member of Armistice Capital, is also deemed to beneficially own these securities.
Sentiment
Score: 6
Explanation: The filing is a routine beneficial ownership report. The continued significant stake (11.43%) by a notable investment firm like Armistice Capital could be viewed as a neutral to slightly positive signal of confidence in the company, although the filing itself does not provide operational or financial performance details.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of significant beneficial ownership in a publicly traded biotechnology company. It indicates a substantial, continued investment by Armistice Capital and Steven Boyd in Aridis Pharmaceuticals, Inc., which is common for institutional investors in the pharmaceutical sector.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's stake, which can influence market perception and liquidity.
Key Dates
| Date | Description |
|---|---|
| 09/30/2024 | Date of shares outstanding calculation for Aridis Pharmaceuticals, Inc. (44,574,021 shares). |
| 11/06/2024 | Date Aridis Pharmaceuticals, Inc. filed its Form 10-Q, reporting shares outstanding. |
| 06/30/2025 | Date of event which requires filing of this statement. |
| 08/14/2025 | Date of filing of this Schedule 13G Amendment No. 5. |
Keywords
Aridis Pharmaceuticals, Armistice Capital, Steven Boyd, Beneficial Ownership, Common Stock, SEC Filing, Schedule 13G, Investment Management, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.